SOPHiA GENETICS and AstraZeneca Expand AI Collaboration for Breast Cancer Treatment
SOPHiA GENETICS has announced an expansion of its collaboration with AstraZeneca to enhance breast cancer treatment outcomes using artificial intelligence, announced in a press release. This multi-year partnership will utilize SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy and real-world impact of therapies for certain types of breast cancer.
The collaboration aims to develop a bespoke AI-powered predictive model to optimize treatment outcomes for breast cancer patients. SOPHiA GENETICS's AI Factories will analyze multimodal healthcare data, including genomics, imaging, and clinical data, to provide insights that can improve patient prognosis and treatment response.
AstraZeneca will use these insights to enhance clinical decision-making and address critical knowledge gaps in breast cancer treatment. The partnership will also focus on generating real-world evidence in Europe and North America to uncover key drivers of treatment efficacy.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 30 Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354 Sep 29 Truven launches MarketScan Snapshot for healthcare data checks Sep 29 Omega Healthcare Wins Gold in 2026 AI Breakthrough Awards Sep 29 Phylo Launches Target Atlas for Drug Target Prioritization Sep 29 ChromAgeNet Detects Aging Signs in Blood Stem Cell ImagesLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Probably Genetic Gets Up to $10M ARPA-H Contract for Rare Disease AI
MediSights Reports Study Using AI Agents for Myeloma Market Research
Astrin Names Medical Director as Certitude Breast Expands Nationwide
SalesSparx and Augment Release SAMI.ai for Healthcare Sales Teams
Domino Data Lab and EPAM Partner on Validated AI for Life Sciences
Daily AI Brief: the AI news that matters, in your inbox.